DE2507974C3 - Copper orotate - Google Patents
Copper orotateInfo
- Publication number
- DE2507974C3 DE2507974C3 DE19752507974 DE2507974A DE2507974C3 DE 2507974 C3 DE2507974 C3 DE 2507974C3 DE 19752507974 DE19752507974 DE 19752507974 DE 2507974 A DE2507974 A DE 2507974A DE 2507974 C3 DE2507974 C3 DE 2507974C3
- Authority
- DE
- Germany
- Prior art keywords
- copper
- orotate
- copper orotate
- salt
- cell systems
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- WKQFGWKSVRJAMI-UHFFFAOYSA-L copper;2,4-dioxo-1H-pyrimidine-6-carboxylate Chemical compound [Cu+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 WKQFGWKSVRJAMI-UHFFFAOYSA-L 0.000 title claims description 10
- 239000010949 copper Substances 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 206010072736 Rheumatic disease Diseases 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 239000005749 Copper compound Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960005010 Orotic Acid Drugs 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N Orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M Copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000003356 anti-rheumatic Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- LROWILPKXRHMNL-UHFFFAOYSA-N copper;thiourea Chemical compound [Cu].NC(N)=S LROWILPKXRHMNL-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001373 regressive Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
2. Pharmazeutische Zubereitung für die Kupfer-Therapie in oraler oder rektaler Verabreichung, gekennzeichnet durch einen Gehalt an Kupfer-orotat neben üblichen Hilfs- und Trägerstoffen.2. Pharmaceutical preparation for copper therapy in oral or rectal administration, characterized by a content of copper orotate in addition to the usual auxiliaries and carriers.
Die Erfindung betrifft das Kupfersalz der Orotsäure der StrukturformelThe invention relates to the copper salt of orotic acid of the structural formula
ιH
ι
Y O
Y
Ύ O
Ύ
I H
I.
N I.
N
NH I.
NH
NN
COO — Cu — OOCCOO - Cu - OOC
und der Bruttoformel Cu(C5H3N204)2. Die erfindungsgemäße Verbindung eignet sich insbesondere zur therapeutischen Verwendung bei der Kupfer-Therapie in oraler oder rektaler Verabreichung.and the gross formula Cu (C 5 H 3 N204) 2. The compound according to the invention is particularly suitable for therapeutic use in copper therapy in oral or rectal administration.
Es wurde gefunden, daß sich Kupfer-orotat in besonders wirksamer Weise für die Behandlung von menschlichen Erkrankungen eignet, die mit einer krankheitstypischen Mobilisierung von Kupfer aus Zellsystemen einhergehen, insbesondere die Behandlung des chronischen Rheumatismus.It has been found that copper orotate is particularly effective for the treatment of human diseases that are characterized by a mobilization of copper that is typical of the disease Cell systems, especially the treatment of chronic rheumatism.
Es ist an sich seit langem bekannt, daß Kupfer-Verbindungen eine interessante Wirkung gegen Rheuma-Erkrankungen entfalten können, z. B. das S-Kupfersalz des N-Allyl-N'-(3-carboxyphenyI)-isothioharnstoffs und Kupfer-Caseinhydrolysat-Komplexe. Diese bekannten Präparate mußten jedoch im Laufe der Zeit aufgegeben werden, weil ihre Giftigkeit, z. B. auf die Nieren, groß war. It has long been known that copper compounds can have an interesting effect against rheumatic diseases, e.g. B. the S-copper salt of N-allyl-N '- (3-carboxyphenyI) -isothiourea and copper-casein hydrolyzate complexes. However, these known preparations had to be abandoned over time because their toxicity, e.g. B. on the kidneys, was great .
Untersuchungen mit dem Ziel einer gerichteten bzw. gezielten Kupfer-Aufladung von entzündlich veränderten Zellsystemen führten nun zum erfindungsgemäßen Kupfer-orotatInvestigations with the aim of a directed or targeted copper charge of inflammatory changes Cell systems now led to the copper orotate according to the invention
Bei am Menschen (16 Patienten) durchgeführten Versuchen mit primär chronischem Gelenkrheumatismus (PcP) ergab sich, daß Kupfer-orotat, im Vergleich zum eingangs erwähnten Kupfer-Isothioharnstoff-Salz 600- bis 800mal stärker wirksam istIn tests carried out on humans (16 patients) with primarily chronic rheumatoid arthritis (PcP) it was found that copper orotate, in comparison to the copper isothiourea salt mentioned at the beginning Is 600 to 800 times more effective
Außerdem wurde bei weiteren Tierversuchen an Impftumoren der Ratte und Spontantumoren der Maus festgestellt, daß Kupfer-orotat stark regressiv wirkt.In addition, in further animal experiments on vaccinated tumors in rats and spontaneous tumors in mice found that copper orotate has a strong regressive effect.
Aufgrund dieser Erkenntnisse stellt sich Kupfer-orotat als ein hochwirksamer, allen bisher bekannten Kupfer-Verbindungen weit überlegener Stoff von antirheumatischer, entzündungshemmender Wirkung dar, der bei hauptsächlich oraler Verabreichung für die Behandlung von menschlichen Erkrankungen, die mit einer krankheitstypischen Mobilisierung von Kupfer aus Zellsystemen einhergehen, insbesondere dem chronischen Rheumatismus, besonders geeignet erscheint.Based on these findings, copper orotate turns out to be a highly effective one known to all Copper compounds far superior substance of anti-rheumatic, anti-inflammatory effects when administered primarily orally for the treatment of human diseases associated with mobilization of copper from cell systems typical of the disease, especially the chronic one Rheumatism, seems particularly suitable.
Kupfer-orotat (bzw. di-orotat) kann synthetisch in der Weise gewonnen werden, daß man bei normaler oder etwas erhöhter Temperatur ein lösliches Kupfersalz in stöchiometrischer Menge in einer wäßrigen Lösung mit Orotsäure umsetzt Das Kupfersalz, z. B. CuCl2 oder Cu(CHsCOO)2, wird unter Rühren langsam eingegeben, wobei Kupfer-orotat ausfällt und abfiltriert wird. Die Kristalle werden mit heißem Wasser gewaschen und dann getrocknet Es entstehen eine türkisfarbene, feinkristalline Substanz, die in den üblichen Lösungsmitteln schwer löslich ist, d. h. ihre Lösungsfähigkeit liegt unter 0,25%; der Schmelzpunkt liegt über 3500C. Die Gehaltsbestimmung im Wege der komplexometrischen Kupfertitration (Fehlergrenze ± 1%) ergibt ber. 1532% Cu.Copper orotate (or di-orotate) can be obtained synthetically in such a way that a soluble copper salt is reacted in a stoichiometric amount in an aqueous solution with orotic acid at normal or slightly elevated temperature. B. CuCl 2 or Cu (CHsCOO) 2 is slowly added with stirring, whereupon copper orotate precipitates and is filtered off. The crystals are washed with hot water and then dried. The result is a turquoise, finely crystalline substance which is sparingly soluble in the usual solvents, ie its solubility is below 0.25%; the melting point is above 350 ° C. The determination of the content by means of complexometric copper titration (error limit ± 1%) results in 1532% Cu.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752507974 DE2507974C3 (en) | 1975-02-25 | Copper orotate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752507974 DE2507974C3 (en) | 1975-02-25 | Copper orotate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2507974A1 DE2507974A1 (en) | 1976-09-02 |
| DE2507974B2 DE2507974B2 (en) | 1977-04-14 |
| DE2507974C3 true DE2507974C3 (en) | 1977-12-01 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2507974C3 (en) | Copper orotate | |
| DE2507974B2 (en) | COPPER OROTATE | |
| DE1518377B1 (en) | Aluminum tri- [N- (3-trifluoromethylphenyl) anthranilate] and process for its preparation | |
| DE1229543B (en) | Process for the preparation of 1, 3-dithia-2-arsacyclopentane-4, 5-dicarboxylic acids | |
| DE2052819C3 (en) | Cytosininosinate, process for its preparation and medicinal products containing it | |
| DE2901914C2 (en) | Zinc salt of 6-N-acetylamino-caproic acid, process for its preparation and pharmaceuticals containing this compound | |
| DE2428039C3 (en) | Medicines with choleretic effects, containing 2,6-dihydroxycineol | |
| DE1793769C2 (en) | Process for the preparation of bis (thiosemicarbazones). Eliminated from: 151205 | |
| DE488610C (en) | Process for the preparation of N-haloalkenyl derivatives of norcodeine | |
| DE2622977C2 (en) | p-Chlorophenoxyisobutyryl-glycine amide, a process for its preparation and a lipid metabolism-promoting agent containing this compound | |
| DE2235400C3 (en) | ^ Chlor-S-sulfamoyl-anthranilic acids, their salts, processes for the preparation of these compounds and medicaments containing these compounds | |
| DE862341C (en) | Process for the preparation of aqueous solutions of derivatives of p-aminobenzene sulfonamide | |
| CH649536A5 (en) | WATER-SOLUBLE DERIVATIVES FROM 6,6'-METHYLENE-BIS (2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE) AND METHOD FOR THE PRODUCTION THEREOF. | |
| AT103978B (en) | Process for the preparation of new arsenic compounds from china bases | |
| DE2901629A1 (en) | 4-PYRIMIDYL SULFIDES, METHOD FOR MANUFACTURING IT, MEDICINAL PRODUCTS AND USES | |
| DE255030C (en) | ||
| DE2521905A1 (en) | FUMARIC SALT OF 1-DIAETHYLAMINO-AETHYL-3-(P-METHOXYBENZYL)-1,2-DIHYDRO-QUINOXALIN-2-ONE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICALS CONTAINING THIS COMPOUND | |
| AT217022B (en) | Process for the production of the new cysteamine orotate | |
| DE1808173B2 (en) | CALCIUM OROTATE | |
| AT205670B (en) | ||
| DE604070C (en) | Process for the production of neutral soluble complex salts of trivalent antimony | |
| DE1518377C (en) | Aluminum square bracket on N- (3-trifluoromethylphenyl) -anthtanilate square bracket and process for its preparation | |
| AT77319B (en) | Process for the preparation of water-soluble compounds of cystine and its derivatives with disinfectants for combating typhoid and other infectious diseases which have their origin in the liver. | |
| DE2235400A1 (en) | 4-CHLORO-5-SULPHAMOYL-ANTHRANILIC ACID DERIVATIVES | |
| DE2007451A1 (en) | Anesthetic drugs for fish |